212 related articles for article (PubMed ID: 37063928)
61. Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma.
Chen GL; Li D; Cao S; Jiang S; Zhang Q; Jin J; Xia Z; Liu Y; Liu X; Zhu Y; Chen Y; Gu L; Hong X; Cao J; Tao R; Lv F
Mediterr J Hematol Infect Dis; 2022; 14(1):e2022066. PubMed ID: 36119461
[TBL] [Abstract][Full Text] [Related]
62. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients.
Gouveia GR; Ferreira SC; Siqueira SAC; de Pádua Covas Lage LA; Hallack Neto AE; de Oliveira Costa R; Pereira J
BMC Cancer; 2020 Oct; 20(1):1041. PubMed ID: 33121489
[TBL] [Abstract][Full Text] [Related]
63. R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma.
Zhao F; Qin Y; Yang J; Liu P; He X; Zhou L; Zhou S; Gui L; Zhang H; Wang X; Jiang S; Zhong Q; Zhou Y; Shi Y
Asia Pac J Clin Oncol; 2020 Dec; 16(6):385-391. PubMed ID: 32779387
[TBL] [Abstract][Full Text] [Related]
64. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma.
Wei X; Huang F; Wei Y; Jing H; Xie M; Hao X; Feng R
Leuk Res; 2014 Jun; 38(6):694-8. PubMed ID: 24713260
[TBL] [Abstract][Full Text] [Related]
65. Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.
Wang S; Wang L; Hu J; Qian W; Zhang X; Hu Y; Zhu Q; Chen B; Wu D; Chang CH; Xu P; Zheng X; Wei J; Liu Y; Cui G; Tang Y; Ma Y; Huang H; Yi H; Zhao W
Cancer Commun (Lond); 2021 Mar; 41(3):229-239. PubMed ID: 33482051
[TBL] [Abstract][Full Text] [Related]
66. [Clinical Features of Diffuse Large B-Cell Lymphoma Transformed from Follicular Lymphoma].
Zhang XL; Yu WJ; Zhu YN; Yang CM; Xiao F; Mai WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1772-1778. PubMed ID: 36476902
[TBL] [Abstract][Full Text] [Related]
67. [Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma].
Zhao SX; Han Y; Zhu Q; Wang Q; Zhang WJ; Chen XC; Sun AN; Jin ZM; Qiu HY; Tang XW; Fu ZZ; He GS; Miao M; Ma X; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):623-7. PubMed ID: 23815910
[TBL] [Abstract][Full Text] [Related]
68. HIV-associated Burkitt lymphoma in the combination antiretroviral therapy era: Real-world outcomes and prognostication.
Wang C; Liang S; Quan X; Guo B; Huang D; Li J; Liu Y
EJHaem; 2023 Feb; 4(1):100-107. PubMed ID: 36819158
[TBL] [Abstract][Full Text] [Related]
69. Diffuse large B-cell lymphoma: A retrospective study from a regional care center in South India.
Babu SM; Garg S; Kanakasetty GB; Kuntegowdanahalli LC; Dasappa L; Rao SA
Indian J Cancer; 2018; 55(1):66-69. PubMed ID: 30147096
[TBL] [Abstract][Full Text] [Related]
70. The clinical features and prognosis of 31 HIV-infected diffuse large B-cell lymphoma cases.
Lian Y; Huang J; Zhao H
Sci Prog; 2021; 104(2):368504211022500. PubMed ID: 34157910
[TBL] [Abstract][Full Text] [Related]
71. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
72. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
73. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
74. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
Montalbán C; Díaz-López A; Martín A; Baile M; Sanchez JM; Sancho JM; García O; Novelli S; Monter-Rovira A; Salar A; Bastos M; Gutiérrez A; Bento L; Córdoba R; Arquero T; González de Villambrosia S; Barranco G; De Oña R; López Guillermo A; Rodriguez Salazar MJ; Domínguez JF; Fernández R; Queizan JA; Rodríguez J; Abraira V; García JF;
Br J Haematol; 2018 Aug; 182(4):534-541. PubMed ID: 29978453
[TBL] [Abstract][Full Text] [Related]
75. Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era.
Jing XM; Yu JR; Luo YK; Zhang SC; Liu JF; Li L; Wu P; Zhang ZH
Leuk Res; 2017 Sep; 60():89-93. PubMed ID: 28772206
[TBL] [Abstract][Full Text] [Related]
76. [Expression of MCP-1 and CCR2 in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Clinical Significance].
Wang M; Zhang PP; Zhu Q; Hu ZL; Bai X; Wu YP; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):112-119. PubMed ID: 38387908
[TBL] [Abstract][Full Text] [Related]
77. Clinical characteristics and outcomes in HIV-associated diffuse large B-cell lymphoma in China: A retrospective single-center study.
Wu J; Miao Y; Qian C; Tao P; Wang X; Dong X; Li X; Lou J; Liang J; Xu W; Li J; Min H
J Cancer; 2021; 12(10):2903-2911. PubMed ID: 33854591
[TBL] [Abstract][Full Text] [Related]
78. Non-germinal center B-cell subtype of pediatric diffuse large B-cell lymphoma in Japan: A retrospective cohort study.
Hori D; Kobayashi R; Nakazawa A; Iwafuchi H; Klapper W; Osumi T; Ohk K; Sekimizu M
Pediatr Blood Cancer; 2023 May; 70(5):e30279. PubMed ID: 36860130
[TBL] [Abstract][Full Text] [Related]
79. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
80. Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
Silverton A; Gunthel C; Adamski M; Mosunjac M; Nguyen ML
AIDS Res Hum Retroviruses; 2014 Jul; 30(7):665-9. PubMed ID: 24707838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
